Cancer drug combo shows promise for patients with rare gene mutation

NCT ID NCT05523440

Terminated Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 06, 2026 · Last updated Jun 11, 2026 · Updated 2 times

Summary

This study tested two treatments—niraparib alone or niraparib plus bevacizumab—in people with recurrent endometrial or ovarian cancer that has a specific change in the ARID1A gene. The goal was to see how many patients' tumors shrank or disappeared. The study was stopped early after enrolling only 9 participants, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

University of Oklahoma Health Sciences Center, Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
University of Virginia Comprehensive Cancer Center

Charlottesville, Virginia, 22903, United States

Conditions

Explore the condition pages connected to this study.

ARID1A GENE MUTATION RECURRENT ENDOMETRIAL CARCINOMA RECURRENT OVARIAN CARCINOMA

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

RECURRENT ENDOMETRIAL CANCER WITH ARID1A MUTATION